Starton Holdings, Inc.
STA
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-09-18
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-12.24
-
-
226.34M
Biotechnology & Medical Research
2025-12-11
Public Filing
View Prospectus
2026-07-23
Offering
Price Range: 6.00~6.00
Shares to be Issued: 5000.00K
2026-09-17
Offering End Date
Offering Price: 6.00
Post IPO Outstanding: 37.72M
2026-09-18
Listed
No Data
About STA
Starton Holdings, Inc. is a clinical-stage biotechnology company. It is focused on improving standard-of-care therapies for people with cancer through application of its proprietary platform of delivery technology systems. Its lead development programs, STAR-LLD, are continuous delivery systems of the generic form of Revlimid (lenalidomide), which is a prescription medicine owned by Bristol Myers Squibb that is used to treat adults with multiple myeloma, mantle cells and other lymphomas. It focuses on multiple indications in multiple myeloma and chronic lymphocytic leukemia, in combination with CAR-T therapies and potentially expanding in other cancers. Its STAR-OLZ product candidate targets an indication in chemotherapy-induced nausea and vomiting. Its platform enables the use of continuous drug delivery using three continuous delivery methods: subcutaneous delivery by ambulatory pump, oral controlled release tablet and/or capsule, and transdermal delivery using patch technology.

Webull offers Starton Holdings, Inc. stock information, including NASDAQ: STA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STA stock methods without spending real money on the virtual paper trading platform.